HYTERA
9.6.2020 03:02:05 CEST | Business Wire | Press release
Imagine one day you get a traffic ticket from the police officers with the penalty amount stating: "Stay Home". Recently, movement restriction rules are being enforced in every Emirate in the UAE. In Abu Dhabi, the police officers patrol the streets round the clock and stress the need for people to stay home. They also urge the community to practice social distancing measures and to wear masks and gloves, when stepping out. The effect and efficiency of their work is being guaranteed by Hytera’s Narrowband & Broadband Convergent Communication Solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200608005013/en/
“During the day, we spread awareness that people should not step out during Sanitization Program and if we spot anyone not wearing a mask, we tell them to put it on. We would give a warning to first-time offenders and impose a Dh 1,000 fine if they're found outside again,” said one of the police officers from the patrols unit. Abu Dhabi Police is responsible for enforcing the compliance with the UAE federal law.
To prevent the spread of Coronavirus, police officers bear an important responsibility for ensuring the public's commitment to the national movement restrictions. The availability of reliable communication services has become an indispensable part to better safeguard citizens both in times of crisis and in normal day-to-day operations.
Abu Dhabi Police have adopted Hytera Narrowband & Broadband Convergent Communication Solution in 2019. Patrol vehicles were equipped with the Hytera Smart devices which support 2G/3G/4G and LTE. This provided the police officers with a converged radio and a smartphone supporting both narrowband and broadband technologies. Smart devices deliver key voice services through the built-in TETRA module, thereby guaranteeing the reliability and security of the Abu Dhabi Police’s daily voice communications. The LTE and Wi-Fi part of the radio provide the broadband data services and application software to support multimedia services, and smart applications used by the Police Enforcement to execute different tasks online, transmit data to the data center and send the required message or safety instructions to the public.
The built-in GPS location functionality of Hytera Smart Devices combined with integrated mapping systems and compasses can upload GPS locations to the Command and Control Center which makes the dispatch task more efficient.
“It is certainly a challenging time for everyone as the pandemic brings significant impact on our life. Many of our users like police and healthcare providers are in the front line of fighting against the virus. As a manufacturer, we believe the secure and reliable communications can make their work more efficient and effective. And as citizens, we all need to practice social distancing to minimize the risk of COVID-19 spreading in the community,” said Stanley Song, Director of the Middle East and North Africa region for Hytera.
For more information, please visit: https://bit.ly/36XU5Dz
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005013/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom